Pharmafile Logo
Pharmafocus logo
Advanced Search

Cara Therapeutics

Showing 3 posts of 3 posts found.

Cara Therapeutics shares data from part a of notalgia paresthetica trial

June 13, 2024
Research and Development Cara Therapeutics, Neurology, clinical trial, notalgia paresthetica, pruritus

Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study which assessed the efficacy and …

News
dw-anzcxqaqavhl

FDA grants Priority Review to Korsuva for CKD-associated pruritis

March 8, 2021
Sales and Marketing Cara Therapeutics, FDA, Korsuva

The FDA has accepted and granted Priority Review for the new drug application (NDA) for Cara Therapeutics’ Korsuva (difelikefalin) solution …

News
handshake_2

Vifor Fresenius snap up rights to Cara’s itch therapy

May 23, 2018
Research and Development, Sales and Marketing Cara Therapeutics, Vifor Fresenius, biotech, drugs, pharma, pharmaceutical

The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025